Results 161 to 170 of about 3,785 (215)
Some of the next articles are maybe not open access.
Phosphodiesterase in Psoriasis
British Journal of Dermatology, 1969SUMMARY. . Phosphodiesterase activity was determined by a fluorometric method using thymidine-5′-3–0-methoxy fluorescein phosphate as a substrate, in blood serum, finger-blood, normal skin, foreskin and psoriatic skin. Higher enzyme activity was found in psoriasis both in blood-serum and finger-blood in comparison with normal controls ...
F, Zaruba, M A, Karasek, E M, Farber
openaire +2 more sources
Lung Phosphodiesterase Isoenzymes
1993The distinct phosphodiesterase isoenzyme activities in guinea-pig lung were identified and characterised. We demonstrate that protein kinase A catalyses the activation of lung Type V cyclic GMP phosphodiesterase. This occurs via a marked change in the Vmax for cyclic GMP hydrolysis.
Pyne, N J, Burns, F
openaire +3 more sources
Phosphodiesterases as therapeutic targets
Urology, 2003The advent of sildenafil (Viagra) for the treatment of erectile dysfunction has attracted widespread interests in phosphodiesterase type 5 (PDE5), the target of sildenafil, 1 and other members of the PDE superfamily. PDEs are intracellular enzymes that catalyze the hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate ...
Ching-Shwun, Lin +3 more
openaire +2 more sources
Phosphodiesterase 4 inhibitors
Journal of the American Academy of Dermatology, 2018Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited
Rema, Zebda, Amy S, Paller
openaire +2 more sources
Electrophysiology of phosphodiesterase inhibitors
The American Journal of Cardiology, 1989Phosphodiesterase inhibitors appear to uniformly enhance atrioventricular node conduction, although milrinone seems to have the least effect. Except for digoxin, this effect on atrioventricular node conduction is similar to that noted with other inotropic agents.
G V, Naccarelli, R A, Goldstein
openaire +2 more sources
Xanthines and Phosphodiesterase Inhibitors
2016Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
D, Spina, C P, Page
openaire +2 more sources
Phosphodiesterase inhibitors and the eye
Clinical & Experimental Ophthalmology, 2009AbstractPhosphodiesterase type 5 (PDE5) inhibitors are effective oral treatments for erectile dysfunction and have become one of the most widely prescribed medications worldwide. The mechanism of action is to reduce the degradation of cyclic GMP (cGMP) potentiating the effect of nitric oxide in the corpus cavernosum and allowing erectile function to ...
Nathan M, Kerr, Helen V, Danesh-Meyer
openaire +2 more sources
Carboxyamidotriazole: A novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases
European Journal of Pharmacology, 2015Carboxyamidotriazole (CAI) is a non-cytotoxic anti-tumor drug, which also shows considerable anti-inflammatory effects in a variety of animal models of inflammation. The exact target and mechanism of CAI were not clearly understood yet. In the present study, we demonstrate that CAI is a non-selective phosphodiesterase (PDE) inhibitor, which provides ...
Lei Guo +8 more
openaire +2 more sources
Cyclic nucleotide phosphodiesterases
Journal of Allergy and Clinical Immunology, 2001Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of physiologic responses. Their intracellular levels are controlled by the complex superfamily of cyclic nucleotide phosphodiesterase (PDE) enzymes. Continuing advances in our understanding of the molecular pharmacology of these enzymes has led
openaire +2 more sources
Phosphodiesterase-5 Inhibitors
2013Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A, Cockrill, Aaron B, Waxman
openaire +2 more sources